We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+12.19%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$35.3M
AUM Growth
+$11.2M
Cap. Flow
+$9.67M
Cap. Flow %
27.41%
Top 10 Hldgs %
98.43%
Holding
14
New
5
Increased
5
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$3.21M
2
GSK icon
GSK
GSK
+$2.01M
3
BIS icon
ProShares UltraShort NASDAQ Biotechnology
BIS
+$1.56M
4
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$1.26M
5
VKTX icon
Viking Therapeutics
VKTX
+$998K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 90.11%
2 Miscellaneous 9.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
Gilead Sciences
GILD
$185B
$7.08M 20.08%
100,000
– –
TYME
2
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$6.56M 18.59%
2,075,000
– –
NVLN
3
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$4.83M 13.7%
1,313,387
+313,387
+31% +$1.26M
GSK icon
4
GSK
GSK
$101B
$4.03M 11.43%
80,000
+40,000
+100% +$2.01M
AGN
5
DELISTED
Allergan plc
AGN
$3.33M 9.45%
+20,000
New +$3.21M
BIS icon
6
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
$2.92M 8.28%
18,750
+9,375
+100% +$1.56M
LAB icon
7
Standard BioTools
LAB
$253M
$2.68M 7.6%
450,000
+39,500
+10% +$225K
AMRN
8
Amarin Corp
AMRN
$299M
$1.54M 4.38%
25,000
+2,500
+11% +$155K
VKTX icon
9
Viking Therapeutics
VKTX
$3.95B
$1.42M 4.04%
+150,000
New +$998K
AMRN
10
CALL
Amarin Corp
AMRN
$299M
$309K 0.88%
+5,000
New +$310K
ATRS
11
CALL
DELISTED
Antares Pharma, Inc.
ATRS
$258K 0.73%
+100,000
New +$249K
ATRS
12
DELISTED
Antares Pharma, Inc.
ATRS
$258K 0.73%
+100,000
New +$249K
SEEL
13
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$39K 0.11%
1
– –
BIS icon
14
CALL
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
– –
-6,250
Closed -$1.06M

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Healthcare Value Capital held 14 positions worth $35.3M, up 47% from $24.1M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Healthcare Value Capital deployed $9.67M of net new capital in Q2 2018, opening 5 new positions and adding to 5 existing holdings. Its largest new stake was Allergan plc: 20,000 shares worth $3.33M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier, followed by Miscellaneous.

  • Healthcare Value Capital's largest Q2 2018 buy was Allergan plc: 20,000 shares worth $3.33M.
  • Healthcare Value Capital added most to GSK in Q2 2018, an estimated $2.01M increase.
  • Healthcare Value Capital's ten largest holdings make up 98% of its $35.3M portfolio in Q2 2018.
  • Healthcare Value Capital opened 5 new positions and closed 1 in Q2 2018.
  • Healthcare Value Capital's portfolio value rose 47% quarter-over-quarter to $35.3M.

Based on Healthcare Value Capital's 13F filing for Q2 2018, filed 7 Aug 2018.